H.C. Wainwright Upgrades Iterum Therapeutics (ITRM) to Buy

March 15, 2021 6:21 AM

H.C. Wainwright analyst Ed Arce upgraded Iterum Therapeutics (NASDAQ: ITRM) from Neutral to Buy with a price target of $2.50.The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found